Using the biology of chronic lymphocytic leukemia to choose treatment.
about
Chronic lymphocytic leukemia: a clinical review including Korean cohortsChanges in T-cell subpopulations and cytokine network during early period of ibrutinib therapy in chronic lymphocytic leukemia patients: the significant decrease in T regulatory cells number.Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroupsThree-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.IGFBP-2 - taking the lead in growth, metabolism and cancerChronic lymphocytic leukemia: molecular heterogeneity revealed by high-throughput genomicsTo treat or not to treat: metabolomics reveals biomarkers for treatment indication in chronic lymphocytic leukaemia patients.Clinical application of targeted and genome-wide technologies: can we predict treatment responses in chronic lymphocytic leukemia?Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms.B-cell lymphoma mutations: improving diagnostics and enabling targeted therapies.Paradigm shifts in the management of poor-risk chronic lymphocytic leukemia.Pharmacodynamic considerations of small molecule targeted therapy for treating B-cell malignancies in the elderly.TP53 mutation analysis in chronic lymphocytic leukemia: comparison of different detection methods.The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia.Protein kinase D-dependent CXCR4 down-regulation upon BCR triggering is linked to lymphadenopathy in chronic lymphocytic leukaemia
P2860
Q26752467-3EE80FFD-2F0D-426E-AF65-62B8A2C94C02Q33798525-9166CA1E-A9FE-4CF6-8F8B-0812C5667795Q33913537-1595A138-7B86-4EC9-9C5D-311BF71E3271Q35450520-AE5DB85A-F10E-4FE5-979B-D047688CFF4BQ35690628-D6E2BE33-A741-41C1-966E-EDB92924F28DQ36998431-4D63A751-29E4-41B8-90E7-1B5A68488987Q37225538-340B0155-6A29-4EAD-97E7-CA510CA3414AQ37618663-E5EB1447-D586-40DD-92B2-C41C60A44394Q38060535-00B5653A-F480-48AD-A75D-7AB13AFEFE99Q38185363-51C42CA3-153F-4820-ABBB-D2FB4D418DCBQ38259446-72F7CC44-BCEB-4637-96DF-0D502D1D6F87Q38544216-F8225D08-23E3-44F1-BED9-11AE614EBFDEQ39070644-0005CAA3-2AB5-454E-9BD5-8C835468749FQ39180275-A4B86464-20BB-4338-8131-817F4D70A3FCQ39540024-214E2383-3D95-485A-BFF5-D7BE8DE96590
P2860
Using the biology of chronic lymphocytic leukemia to choose treatment.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Using the biology of chronic lymphocytic leukemia to choose treatment.
@en
Using the biology of chronic lymphocytic leukemia to choose treatment.
@en-gb
Using the biology of chronic lymphocytic leukemia to choose treatment.
@nl
type
label
Using the biology of chronic lymphocytic leukemia to choose treatment.
@en
Using the biology of chronic lymphocytic leukemia to choose treatment.
@en-gb
Using the biology of chronic lymphocytic leukemia to choose treatment.
@nl
prefLabel
Using the biology of chronic lymphocytic leukemia to choose treatment.
@en
Using the biology of chronic lymphocytic leukemia to choose treatment.
@en-gb
Using the biology of chronic lymphocytic leukemia to choose treatment.
@nl
P1476
Using the biology of chronic lymphocytic leukemia to choose treatment.
@en
P304
P356
10.1182/ASHEDUCATION-2011.1.104
P577
2011-01-01T00:00:00Z